Some countries, such as Japan, have no universal vaccination program for HAV infection, and drug development for hepatitis A could be useful for controlling HAV infection and preventing severe hepatitis A. In conclusion, MAP2K3 could be one of the modulation factors for HAV PAMP triggers that produce interferon-β. Here, MAP2K3 is linked to hepatitis A virus infection.